key: cord-0709769-lm3c262v
authors: nan
title: CKD: The burden of disease invisible to research funders
date: 2022-04-26
journal: Nefrologia (Engl Ed)
DOI: 10.1016/j.nefroe.2021.09.005
sha: 669bac1a74c665b27c13a70006ba92ddbdb8c469
doc_id: 709769
cord_uid: lm3c262v

The uptake of the current concept of chronic kidney disease (CKD) by the public, physicians and health authorities is low. Physicians still mix up CKD with chronic kidney insufficiency or failure. In a recent manuscript, only 23% of participants in a cohort of persons with CKD had been diagnosed by their physicians as having CKD while 29% has a diagnosis of cancer and 82% had a diagnosis of hypertension. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. A prevalent view is that for those in whom kidneys fail, the problem is “solved” by dialysis or kidney transplantation. However, the main burden of CKD is accelerated aging and all-cause and cardiovascular premature death. CKD is the most prevalent risk factor for lethal COVID-19 and the factor that most increases the risk of death in COVID-19, after old age. Moreover, men and women undergoing KRT still have an annual mortality which is 10–100-fold higher than similar age peers, and life expectancy is shortened by around 40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth global cause of death by 2040 and the second cause of death in Spain before the end of the century, a time when 1 in 4 Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded CIBER network research structure in Spain. Leading Spanish kidney researchers grouped in the kidney collaborative research network REDINREN have now applied for the RICORS call of collaborative research in Spain with the support of the Spanish Society of Nephrology, ALCER and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true. However, only the highest level of research funding through the CIBER will allow to adequately address the issue before it is too late.

r e s u m e n El impacto del concepto actual de enfermedad renal crónica (ERC) en la población, médicos y autoridades sanitarias ha sido bajo. Los médicos aún confunden la ERC con la insuficiencia renal crónica. En un manuscrito reciente, en una cohorte de personas con ERC, solo el 23% de los participantes fueron diagnosticados de ERC por sus médicos mientras que el 29% estaban diagnosticados de cáncer y el 82% de hipertensión. Para el público en general y las autoridades sanitarias, la ERC evoca la terapia de reemplazo renal (TRR). En España, la prevalencia de TRR es del 0,13%. La opinión predominante es que para aquellos en los que fallan los riñones, el problema se "resuelve" mediante diálisis o trasplante de riñón. Sin embargo, la principal carga sanitaria de la ERC es el envejecimiento acelerado y la muerte prematura de causa cardiovascular o de cualquier causa. La ERC es el factor mas prevalente de riesgo de mortalidad por COVID-19 después de la edad avanzada.

Además, los hombres y mujeres que se someten a TRR todavía tienen una mortalidad anual que es de 10 a 100 veces superior a sus pares de edades similares, y la esperanza de vida se reduce en alrededor de 40 años para jóvenes en diálisis y en 15 años para jóvenes con un injerto renal funcionante.

Se espera que la ERC se convierta en la quinta causa mundial de muerte para 2040 y la segunda causa de muerte en España antes de fin de siglo, época en la que 1 de cada 4 españoles tendrá ERC.

Sin embargo, para 2022, la ERC se convertirá en la única causa de muerte entre las 15 principales a nivel mundial que no cuenta con el respaldo de una estructura de investigación CIBER en España.

Los Principales grupos de investigación renal en España agrupados en la red de investigación colaborativa renal REDINREN han solicitado la convocatoria RICORS de investigación colaborativa en España con el apoyo de la Sociedad Española de Nefrología, ALCER y ONT:

RICORS 040 tiene como objetivo evitar que se hagan realidad las terribles predicciones sobre la carga mundial de ERC para 2040. Sin embargo, solo el más alto nivel de financiación de la investigación a través del CIBER permitirá abordar adecuadamente el problema antes de que sea demasiado tarde. The present manuscript summarizes key features of the concept of chronic kidney disease (CKD), as well as information on the current and future burden of CKD, and evidence that CKD as a health issue is underestimates by Spanish Health Research funding agencies. A more extensive report has been previously published. 1 The signatories believe that the current and future burden of CKD, which is projected to hit hardly countries with long life expectancy and an ageing population such as Spain constitutes a national emergency that require the highest level available of research funding through the CIBER organization.

CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. 2 Criteria that by themselves diagnose CKD include glomerular filtration rate (GFR) < 60 ml/min/1.73 m 2 or evidence of kidney damage such as pathological albuminuria (urinary albumin creatinine ratio, UACR ≥ 30 mg/g), abnormal urine sediment, histology or imaging, abnormalities due to tubular disorders, or kidney transplantation. 3 Diagnosing CKD implies assigning cause and G (GFR: G1 through G5) and A (albuminuria: A1 through A3) categories. G1 (GFR ≥ 90 ml/min/1.73 m 2 ) and A1 (UACR < 30 mg/g) categories are not diagnostic of CKD by themselves. Persons in category G1A1 require to fulfill an additional criterion to be diagnosed of CKD, such as imaging diagnostic of polycystic kidney disease (PKD). 2, 3 Persons with CKD are at an increased risk of progressing to require kidney replacement therapy (KRT), of all-cause and cardiovascular death, and of acute kidney injury (AKI). 2, [4] [5] [6] There is a bidirectional relationship between CKD and AKI. CKD is the main risk factor for AKI and AKI may accelerate CKD. 7 AKI has a high mortality and increases the risk of death for over a year after the episode. 7 AKI is also common, as around 5% of hospitalized patients develop in-hospital AKI. 8 More recently, CKD has been identified as the most prevalent risk factor for lethal coronavirus disease 2019 (COVID- 19) , and as the factor that most increased the risk of death in COVID-19 after older age [9] [10] [11] (Fig. 1) . AKI is also common in COVID-19 and a key risk factor for death. 9 Increasing CKD categories are associated with increasing risk of all-cause and cardiovascular death, even in the elderly, thus questioning the concept of a "physiological" decrease in eGFR with age ( Fig. 2A, B ). Albuminuria as low as > 2.5 mg/g is already associated with an increased risk of premature death (Fig. 2B) . Thus, the current albuminuria threshold used to diagnose CKD is a late event. Additionally, by the time GFR falls to 60 ml/min/1.73 m 2 , CKD has progressed unnoticed (potentially over years and even decades) to destroy > 50% of the functioning kidney mass. This is the so-called blind spot in the diagnosis of CKD (Fig. 2C) . In this regard, there is clear margin for earlier diagnosis and therapy of CKD. The autosomal dominant PKD paradigm illustrates the way to go: a diagnostic test (sonography) allows the diagnosis of CKD decades before patients fulfill any other criterion to diagnose CKD. Similar diagnostic tools are needed for other forms of CKD. Additional future criteria to diagnose CKD may be include genetic tests disclosing clearly pathogenic gene variants or urinary biomarkers beyond UACR, such as urinary peptidomics or urinary Klotho. [12] [13] [14] Kidney failure (end-stage kidney disease, G5, GFR < 15 ml/min/1.73 m 2 ) is the only form of kidney disease well known to the wider public, non-nephrologists and healthcare authorities. Non-experts usually equate the burden of CKD with the burden of KRT for kidney failure as the 64,000 persons on KRT in Spain consume 2.5-5.0% of the is associated with an increased risk of death even in the very elderly. All-cause mortality rate (absolute risk) for different eGFR (A) and UACR (B) values by age categories based on weighted average across cohorts, adjusted for covariates. A steeper slope at older age indicates a higher absolute risk difference associated with low eGFR as compared with younger age categories: the discontinuous green line represents the overlay of the risk for the very elderly on top of the risk line for the younger age range. Similar trends were observed for albuminuria. Conceptual representation of data presented in 5. In panel A, an increase in the risk of death observed in patients older than 55 years with higher eGFR values is not shown as this is thought to be an artifact depending on lower muscle mass of patients who were sicker at baseline. (C) The blind spot in CKD, as illustrated by autosomal dominant polycystic kidney disease. In ADPKD, CKD is present from birth, but using conventional criteria to diagnose CKD as low eGFR or pathological albuminuria, it can only be diagnosed 30-40 years later. However, there is a diagnostic test, sonography, that allows a much earlier diagnosis by demonstrating the presence of kidney cysts. Diagnostic tests should be developed that allow to diagnose CKD from other, non-ADPKD, causes decades earlier than current GFR or albuminuria criteria allow (figure from ref. 13). Reproduced from 1. healthcare budget. However, the bulk of the health burden of CKD is not represented by KRT but by accelerated aging and premature death, as clearly quantified by Global Burden of Disease (GBD) data discussed below. 15 Illustrating the lack of awareness of the CKD concept, in a recent report of a cohort of persons selected because they had CKD, as evidence for low eGFR for at least 3 months, CKD was only the sixth more common diagnoses after hypertension (82%), cardiovascular disease (39%), cancer (29%), diabetes (29%), heart failure (28%) (Fig. 3) . 16, 17 Thus, only 23% of participants in the CKD cohort had been diagnosed by their physicians as having CKD while the number should be 100%.

KRT is one of the success stories of health care in the 20th century and allows survival following failure of a vital organ. However, KRT is a failure of CKD management that, if successful, should have prevented CKD progression this stage. Indeed, in persons on KRT expected remaining lifetimes are severely reduced -by around 70% (40 years less) and by 25% (15 years less) for a 20-year-old on dialysis or with a functioning kidney graft, respectively. 18, 19 The absolute reduction in expected remaining lifetimes is milder at older ages, but the relative reduction in life expectancy remains constant up to age 89 years (Fig. 4A) . Annual mortality of persons on KRT is up to 100-fold higher than for similar aged controls. 6 Indeed, the 5-year survival of patients on dialysis is lower than for all forms of cancer combined 20 (Fig. 4B ).

The most common cause of KRT in Spain is diabetes (25% of persons initiating KRT), followed by unknown (15%), "vascular", glomerulonephritis (14%) and inherited kidney disease. 18, 19, 21 While PKD is the only inherited kidney disease usually reported by large registries, recent Madrid and Catalonian KRT registry data found all inherited kidney diseases combined as frequent as glomerulonephritis. 22 Inherited kidney diseases are frequently overlooked by physicians. Indeed, whole exome sequencing found monogenic kidney diseases in 9% of adult CKD, and in 17-34% of those with CKD of unknown cause. 23, 24 "Vascular" is labeled as hypertension in the European Renal Association -European Dialysis and Transplant Association (ERA-EDTA) Registry. 18, 19, 21 In clinical practice, hypertension is usually listed as a cause when there is no other obvious etiology, following expert recommendation. 25 This practice may replace an inadequate etiologic workup, downplaying the incidence of other causes of CKD while falsely boosting hypertension as cause (rather than as consequence) of CKD. 26, 27 Thus, there is no relationship between prevalence of hypertension and of hypertensive CKD in different countries. 26 In African Americans, hypertensive nephropathy is known 15 CKD is marked by empty rectangles. Logos to the right correspond to ISCIII-funded collaborative research networks in Spain that will address each cause from 2022. At the time of this writing, the status of kidney research in 2022 is still unclear. An infectious disease CIBER will be created in 2022, but at his point we are unaware of the logo. Thus, the CIBER logo was used and the word "INFEC" was added. Reproduced from 1.

shown but it is projected to become the first cause of death before the end of the century, well above the others. Past growth according to GBD 2016 Spain was projected into the future. 32 The projection did not consider the progressive aging of the Spanish population. Thus, it represents an underestimation of CKD-related deaths. (B) Number of adults with CKD in Spain, by gender and overall, according to the ERICA study from 2010 and projection into the future assuming the same prevalence of CKD by age category and considering changes in the Spanish population age pyramid according to the World Health Organization (WHO) predictions. [33] [34] [35] Since the increasing mean age within each age category was not considered, this projection represents an underestimation. 33 to represent a familial predisposition to CKD triggered by different causes, including human immunodeficiency virus (HIV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 28 In the ERA-EDTA Registry data for all countries, the most common cause of incident KRT was unknown (27%, increasing to 39% if we add hypertension) followed by diabetes (20%), glomerulonephritis (11%) and PKD (5%). For prevalent KRT, the ranking is unknown (27%, increasing to 35% by adding hypertension) followed by glomerulonephritis (19%), diabetes (15%), and PKD (8%). 18, 19 Thus, a significant percentage of persons lack an etiological diagnosis, which precludes etiology-targeted therapy and early prevention campaigns. Among the fastest growing segment of CKD patients (those aged ≥ 65 years), unknown and hypertension accounted for 43% of incident KRT patients, highlighting the need to define cause in the elderly. We propose that accelerated kidney aging may be a key contributor to CKD, including in the elderly, and are currently devising a working definition for accelerated kidney aging that spurs research in this field.

Globally, around 850 million persons have CKD. 29 In 2017, 1.2 million people died from CKD globally and CKD resulted in 35.8 million disability adjusted life years (DALYs), most of them (>70%) not due to diabetic kidney disease, as well as in 7.3 million years lived with disability (YLD) and 28.5 million years of life lost (YLLs) (30) (Fig. 5A) . However, there are large geographical differences in CKD burden. Age-standardized CKD DALY rates varied more than 15-fold between countries, a variability also evident within Spain and even within Spain autonomous communities. 18,30 This illustrates the need for identification and correction of the drivers of a higher burden in certain regions.

GBD projected that CKD will become the 5th global cause of death by 2040 15 (Fig. 5B ). YLLs due to CKD are expected to double by 2040, the fastest increase among major causes of death, after Alzheimer. By contrast, the burden of other major causes of death (e.g. ischemic heart disease −3.6% or stroke −10.7%) is already decreasing. CKD growth as a cause of death outpaces diabetes and research is needed in diabetesindependent causes of CKD. Spain GBD data identified CKD as the 8th cause of death. However, official Instituto Nacional de Estadistica (INE) data underestimated the burden of CKD, likely due to low awareness of the condition. 31, 32 Spain GBD identified CKD as the 2nd fastest growing cause of death, the 6th fastest growing cause of YLD and the 7th fastest growing cause of DALYs among the top 25 causes for each category. 31, 32 Projecting into the future the recent rate of increase of CKD in Spain GBD, CKD will become the 2nd cause of death, after Alzheimer, before the end of the century 32 (Fig. 6A ). This is likely an underestimation, as the progressive change in the age pyramid over the next few decades was not considered. Spanish projections may also apply to other countries with long life expectancy.

The population of Spain will become progressively older and decrease to around 23-33 million by 2100. 33, 34 In 2010, 14% of Spanish adults (6.7 million) had CKD. 35 CKD was more common in men than in women and in those aged 45-64years. Projecting these numbers into the future in the absence of changes to the current standard of care, assuming a constant prevalence of CKD within each age range and gender group and using WHO population prediction estimates, results in at least 8.12 million persons with CKD by 2040 and 7.96 million by 2100, which will represent 18% and 24% of the Spanish population, respectively (Fig. 6B, C) . This is an underestimation, as progressive aging of the population (persons aged 65 years or more are estimated to increase from 17% in 2010 to 32% by 2040 and 35% by 2100) will also occur within the same age range category, and this would be associated with an increased prevalence of CKD within age categories, that we did not consider. Additionally, by 2040, most persons with CKD will be 65-year-old or older.

The prevalence of KRT in Spain is also increasing. It increased 38% from 2007 to 2019 (985-1367 pmp) and the rate appears to be accelerating (it increased 14% from 2007 to 2013 and 22% from 2013 to 2019). At this rate of growth, the number of persons on KRT will hit 0.23-1.00 million by the end of the century, i.e. around 1-4% of the projected population of Spain at that time (Fig. 6D) . The incidence of KRT also increased by 22% from 2013 to 2019 (125-152 pmp) 21 (Fig. 6E) . A majority of persons on KRT in Spain (55%) have a functioning kidney graft. Thus, improving kidney and person outcomes in kidney graft recipients is a major aim in kidney research. As for CKD, KRT is also more common in men than in women. Thus, studies on CKD or KRT that do not split by gender may reflect the 9 -RICORS2040 concept and overall structure and research aims. RICORS2040 aims at improving kidney and person outcomes in both men and women with CKD. There are two set of aims. The first set aims at improving the diagnosis and management of the most common causes of CKD to prevent or delay CKD progression. For this, the main causes of native kidney CKD (diabetes, glomerular, inherited/genetic) will be addressed, and the accelerated kidney aging concept will be explored as a final common pathway of CKD progression and as a potential cause of CKD in persons in whom no other cause is identified. Since the life expectancy of kidney allografts is markedly shorter than for native kidneys, chronic allograft dysfunction will also be explored. The second set aims to improve person outcomes by optimizing the diagnosis and management of the consequences of CKD (or of kidney transplantation therapy) on other organs and systems, what we have collectively named as the accelerated biological aging of CKD. Please note that aim 4 is focused on accelerated kidney aging as a cause of CKD and on kidney events, while aim 6 is focused on the impact of CKD on other organs and systems, that is, on accelerated biological aging of diverse organs and systems occurring as a consequence of CKD. Care will be taken to identify and optimize the management of gender-related issues and provide clinical guidance with specific information for men and for women. Reproduced from 1.

disease in men and studies addressing risk stratification, diagnosis and therapeutic approaches independently for men and for women are required. Furthermore, there are large regional differences (range of incident KRT 85-197 pmp and of prevalent KRT 740-1567 pmp for different Spanish regions), which are also observed within regions (e.g. in Madrid, range of incident KRT 50-200 pmp and of prevalent KRT 980-1700 pmp for different healthcare catchment areas). The causes of these differences are not fully understood, but it is critically important to define them in order to identify and target factors that generate CKD hotspots or benchmark potential healthcare contributors. 36 The burden of CKD is also economical. The extrapolated annual cost of all CKD is at least as high as that for cancer or diabetes and estimated at over 140 billion euros annually in Europe and over 130 billion dollars in the United States 20,37 (Fig. 7) .

From 2022, the Instituto de Salud Carlos III (ISCIII, Spain Government Agency that funds health research) will fund the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS, Cooperative Research Networks Focused on Results in Health) program of network research. This will replace the prior ISCIII-funded program of network research termed RETICS. The Spanish kidney research community, represented by the research groups integrated into the Kidney Research Network RETIC (RETIC RED de INvestigación RENal, REDINREN) and by several working groups of the Spanish Society of Nephrology (Sociedad Española de Nefrología, SEN), such as GLOSEN (glomerular disease working group) and GEENDIAB (diabetes working group), has submitted the RICORS2040 proposal to the RICORS call. RICORS2040 is supported by SENEFRO, the ERA-EDTA, ALCER (Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón, Spanish Kidney Patients Association) and ONT. RICORS2040 is focused on kidney diseases within one of the four thematic areas of the RICORS call: "Inflammation and immunopathology of organs and systems". 38 This thematic area includes kidney diseases and also non-transmissible immune system diseases, allergic diseases, multiple sclerosis and eye diseases.

CKD as a chronic inflammatory disease. CKD is a local inflammatory disease that becomes a systemic inflammatory disease as it progresses. Activation of the master regulator of inflammation (NFB), local expression of inflammatory cytokines and immune cell infiltrates are already observed in early stages of CKD and can be triggered by albuminuria, hyperglycemia and genetic defects, among others 39, 40 (Fig. 8A) . Kidneys have multiple functions and GFR is just one of them. There is increasing evidence that production of the antiaging and anti-inflammatory factor Klotho is a key function of kidney tubules that is lost very early in the course of CKD (GFR category G1, that is, normal "kidney function") partly in response to local inflammation and/or albuminuria 41-43 (Fig. 8B) . Loss of anti-inflammatory molecules and Table 1 -Aims of RICORS2040.

Specific aims:

1. Improve kidney outcomes in men and women with diabetes or diabetic kidney disease (DKD) Improve risk stratification in DKD to foster precision Nephrology Evaluate novel strategies for kidney protection through therapeutic drug repositioning Develop, evaluate and update Spanish Clinical Practice Guideline for detection and management of DKD.

Improve risk stratification in glomerular disease to foster precision Nephrology Evaluate novel kidney protective approaches in primary glomerular disease Develop, evaluate and update clinical guidance documents 3. Improve kidney outcomes in men and women with inherited kidney disease Increase awareness of inherited kidney disease with special focus on glomerular and tubular kidney disease Improve risk stratification in inherited glomerular disease to foster precision Nephrology Identify genetic predictors of CKD progression Develop, evaluate and update clinical guidance documents

Develop a working definition of accelerated kidney aging Develop tools to predict and assess rapid CKD progression Test novel therapeutic approaches to kidney protection Develop, evaluate and update clinical guidance documents

Improve the outcome of chronic allograft nephropathy, decreasing graft loss Limit the negative impact of immune suppressive therapies on comorbidities and life-threatening complications. Develop, evaluate, and update clinical guidance documents for precision immunosuppression

Develop novel risk stratification tools for cardiovascular disease and CKD-MBD to foster precision Nephrology Improve the recognition and outcome of frailty Evaluate the long-term safety and efficacy of SARS-CoV-2 vaccines in persons with advanced CKD Develop, evaluate, and update clinical guidance documents on key consequences of CKD, such as cardiovascular disease, CKD-MBD, frailty and susceptibility to severe SARS-CoV-2 infection

The general aim of RICORS2040 is to improve kidney and person outcomes in men and women with CKD or at high risk of CKD. The name derives from the aim to prove wrong the dire predictions regarding the global burden of CKD by 2040, that closely reflect those for Spain: The GBD collaboration predicts that CKD will become the 5th global cause of death by 2040. accumulation of uremic toxins leads to systemic inflammation, which is a key predictor of cardiovascular events and death in CKD, likely contributing to the accelerated biological aging that characterizes CKD. 44, 45 Current versus future burden: The decade of the kidney. Current research should be guided by future projections of disease burden rather than by past statistics. RICORS2040 derives its name from its aim to prove wrong projections that CKD will become the 5th global cause of death by 2040.

Emphasis on prevention. RICORS2040 is focused on preservation of native and graft kidney function and in improving outcomes in persons with CKD by preventing systemic consequences of CKD, collectively grouped into the concept of accelerated biological aging, including consequences of kidney transplantation and its therapy (Fig. 9) , as a majority of persons on KRT in Spain carry a kidney graft. Thus, preventing the need for KRT in men and women with native kidneys or kidney grafts and improving kidney and person outcomes in kidney graft recipients are major aims of RICORS2040. Risk stratification and optimization of therapeutic approaches to improve quality of life and life expectancy in the dialysis population are also addressed.

Men and women. There is mounting evidence that CKD course and complications are not the same in men and women and even that the cut-off points to define CKD may differ. 46 However, we still use the same metric and the same cutoff points to diagnose CKD and for risk stratification in men and women, even knowing that creatinine excretion differs and thus, the denominator for UACR differs for men and for women. RICORS2040 will address the factors behind the gender gap in CKD burden and aims to provide clinical guidance for both men and women and to identify information gaps that preclude a gender-conscious approach to the diagnosis, risk stratification and treatment of CKD.

Addressing regional inequality. RICORS2040 will also address the factors behind geographical differences in CKD burden as it incorporates multiple centers from all over Spain. Specifically, kidney research and care centers from 12 of the 17 Spanish regions (Autonomous communities) encompassing 90% of the Spanish populations, are integrated into RICORS2040.

Clinical guidance should be implemented. A key issue hampering the achievement of health outcome targets in the poor implementation of clinical guidance documents. In this regard, clinical guidance documents are rarely validated in real-world clinical practice to assess potential shortcomings or barriers to implementation. RICORS2040 will use continuous improvement approaches to generate, validate and improve clinical guidance documents for different causes of CKD as well as for assessing and slowing the progression of CKD and of the associated accelerated biological aging of organs and systems in men and women with native kidneys or with kidney grafts. Testing the implementation of clinical guidance documents in a high number of centers from different regional health systems under real world conditions will allow to identify and correct most shortcomings and feasibility issues.

In summary, RICORS2040 is focused on decreasing the need for KRT by improving prevention, diagnosis, and therapy for major causes of CKD (diabetic, glomerular, inherited, accelerated kidney aging, the latter a concept that RICORS2040 is developing) in native kidneys and of chronic allograft nephropathy as well as on improving outcomes of men and women with CKD by preventing, identifying and treating major consequences of CKD or its therapy that contribute to the burden of accelerated aging and premature death ( Table 1 ). This will be achieved through systematization of prior knowledge generated by its antecessor REDINREN and the international community into gender-conscious clinical guidance documents, novel research to address gaps of knowledge and monitoring of clinical guidance implementation to generate updated clinical guidance documents as output of RICORS2040.

Despite CKD being the 5th predicted global cause of death by 2040, there is no confirmed Spanish research network on CKD from 2022 on. This is in contrast to a wider global movement to increase awareness of the health burden of CKD, summarized in the Decade of the Kidney (2020-2030) strategy in Europe and the US promoted by the American Association of Kidney Patients (AAKP) and adopted by the Advancing American Kidney Health (AAKH) initiative of the United States Government, the European Kidney Health Alliance (EKHA) and by patient associations across Europe. 20, 37, [47] [48] [49] Moreover, even if RICORS2040 is funded, CKD lacks dedicated research centers (e.g. Spanish National Cancer Research Center, CNIO and Spanish National Cardiovascular Research Center, CNIC) or well-funded ISCIII CIBER research networks that fund research on all other major predicted 2040 global causes of death, except CKD 14 : ischemic heart disease (CIBERCV), stroke (CIBERCV and from 2022, stroke RICORS), infection (CIBER from 2022) and chronic obstructive pulmonary disease (CiberRes). ISCIII research networks also fund projected 2040 causes of death ranked below CKD (e.g. CIBERONC for cancer and CIBER-DEM for diabetes) (Fig. 5B ). This represents a major, correctable gap in Spain's health research funding structure.

REDINREN RD16/0009.

On October 13 2021, it was made public that RICORS2040 would be funded by ISCIII starting 2022. 

Sociedad Española de Nefrología (SENEFRO) council, Sociedad Española de Trasplante (SET) council, Organización Nacional de Trasplantes (ONT). RICORS2040: the need for collaborative research in chronic kidney disease

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Clarifying the concept of chronic kidney disease for non-nephrologists

Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data

Age and association of kidney measures with mortality and end-stage renal disease

Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure

Acute kidney injury and chronic kidney disease as interconnected syndromes

Development and internal validation of a prediction model for hospital-acquired acute kidney injury

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Factors associated with COVID-19-related death using OpenSAFELY

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Novel urinary biomarkers for improved prediction of progressive eGFR loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease

Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories

Use of nephrotoxic medications in adults with chronic kidney disease: parallel cohort studies in Swedish and U.S. Routine Care. Clin Kidney

More on the invisibility of CKD. . .. and counting

The ERA-EDTA Registry Annual Report 2017: a summary

Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney

Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports

Diagnostic utility of exome sequencing for kidney disease

The Irish kidney gene project -prevalence of family history in patients with kidney disease in Ireland

Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis. literature review current through

Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology

Hypertension-associated kidney disease: perhaps no more

COVID-19 and APOL1: understanding disease mechanisms through clinical observation

A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases

Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study

The burden of disease in Spain: Results from the Global Burden of Disease 2016. La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades

The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem

Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study

Chronic kidney disease in Spain: prevalence and impact of accumulation of cardiovascular risk factors. Prevalencia de enfermedad renal crónica en España: impacto de la acumulación de factores de riesgo cardiovascular

CKD hotspots around the world: where, why and what the lessons are. A CKJ review series

Kidney-related research in the United States: a position statement from the National Kidney Foundation and the

NF-kappaB in renal inflammation

Albumin downregulates Klotho in tubular cells

Klotho deficiency causes vascular calcification in chronic kidney disease

The inflammatory cytokines TWEAK and TNF␣ reduce renal klotho expression through NFB

Arterial "inflammaging" drives vascular calcification in children on dialysis

Chronic kidney disease and premature ageing

Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

Gender, albuminuria and chronic kidney disease progression in treated diabetic kidney disease

Advancing American Kidney Health (AAKH): catalyst for investment in kidney diseases clinical trials and precision medicine: an opportunity to advance upstream interventions and the importance of nephrology